CoChat
Sign Up
Cited by 72Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsDown syndrome and intellectual disability research

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome

Open access
Lleó, Alberto, Zetterberg, Henrik, Pegueroles, Jordi, Karikari, Thomas K., Carmona-Iragui, María, Ashton, Nicholas J., Montal, Victor, Barroeta, Isabel +18 more·2021·Nature Communications
DOI 10.1038/s41467-021-24319-xPMC PMC8280160
Open this paper in CoChat — free accountOpen PDF

Abstract

Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer’s disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73–0.87] and 0.92 [95% CI 0.89–0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-24319-x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • This relationship is observed across the AD continuum, including the asymptomatic phase in sporadic and genetic forms of AD.

    “This relationship is observed across the AD continuum, including the asymptomatic phase in sporadic and genetic forms of AD.11,12,13,14”

    From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [12]

    The Results (Group comparisons and diagnostic accuracy of p-tau181; page unavailable) report that plasma p-tau181 changes were detectable before expected prodromal diagnosis in adults with Down syndrome. The Discussion says this pattern resembles findings in sporadic and autosomal-dominant AD, but the paper does not establish the unspecified relationship throughout the continuum, including the asymptomatic phase, in both forms of AD. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 23

  1. [1]Ballard C Mobley W Hardy J Williams G Corbett A Dementia in Down’s syndrome Lancet Neurol. 2016 15 622 636 10.1016/S1474-4422(16)00063-6 27302127 · DOI
  2. [2]Bittles AH Bower C Hussain R Glasson EJ The four ages of Down syndrome Eur. J. Public Health 2007 17 221 225 10.1093/eurpub/ckl103 16857692 · DOI
  3. [3]McCarron M A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome J. Intellect. Disabil. Res. 2017 61 843 852 10.1111/jir.12390 28664561 · DOI · Paper page
  4. [4]Fortea J Clinical and biomarker changes of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study Lancet 2020 395 1988 1997 10.1016/S0140-6736(20)30689-9 32593336 PMC7322523 · DOI · Paper page
  5. [5]Hithersay R Association of dementia with mortality among adults with Down syndrome older than 35 years JAMA Neurol. 2019 76 152 160 10.1001/jamaneurol.2018.3616 30452522 PMC6439956 · DOI · Paper page
  6. [6]Startin CM Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease Alzheimers Res. Ther. 2019 11 26 10.1186/s13195-019-0477-0 30902060 PMC6429702 · DOI
  7. [7]Fortea J Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study Lancet Neurol. 2018 17 860 869 10.1016/S1474-4422(18)30285-0 30172624 · DOI
  8. [8]Henson RL Cerebrospinal fluid biomarkers of Alzheimer’s disease in a cohort of adults with Down syndrome Alzheimers Dement. (Amst.) 2020 12 e12057 32671183 PMC7346867
  9. [9]Zetterberg H Burnham SC Blood-based molecular biomarkers for Alzheimer’s disease Mol. Brain 2019 12 26 10.1186/s13041-019-0448-1 30922367 PMC6437931 · DOI
  10. [10]Khalil M Neurofilaments as biomarkers in neurological disorders Nat. Rev. Neurol. 2018 14 577 589 10.1038/s41582-018-0058-z 30171200 · DOI · Paper page
  11. [13]Schindler SE High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis Neurology 2019 93 e1647 e1659 31371569 PMC6946467
  12. [14]Karikari TK Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts Lancet Neurol. 2020 19 422 433 10.1016/S1474-4422(20)30071-5 32333900 · DOI · Paper page
  13. [15]Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat. Med. 26, 387–397 (2020). PMC7101073 32123386
  14. [16]Janelidze S Plasma p-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia Nat. Med. 2020 26 379 386 10.1038/s41591-020-0755-1 32123385 · DOI · Paper page
  15. [17]Mielke MM Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography Alzheimers Dement. 2018 14 989 997 10.1016/j.jalz.2018.02.013 29626426 PMC6097897 · DOI · Paper page
  16. [18]Palmqvist S Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders JAMA 2020 324 772 781 10.1001/jama.2020.12134 32722745 PMC7388060 · DOI · Paper page
  17. [20]Tatebe H Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and Down syndrome Mol. Neurodegener. 2017 12 63 10.1186/s13024-017-0206-8 28866979 PMC5582385 · DOI
  18. [22]Dubois B Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria Lancet Neurol. 2014 13 614 629 10.1016/S1474-4422(14)70090-0 24849862 · DOI · Paper page
  19. [23]Fagan AM Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease Sci. Transl. Med. 2014 6 226ra230 10.1126/scitranslmed.3007901 PMC4038930 24598588 · DOI · Paper page
  20. [24]Lleó A Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer’s disease continuum in the BIOMARKAPD study Alzheimers Dement. 2019 15 742 753 10.1016/j.jalz.2019.01.015 30967340 · DOI
  21. [25]Bateman RJ Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N. Engl. J. Med. 2012 367 795 804 10.1056/NEJMoa1202753 22784036 PMC3474597 · DOI · Paper page
  22. [27]Jennings D Age dependence of brain beta-amyloid deposition in Down syndrome: an [18F]florbetaben PET study Neurology 2015 84 500 507 10.1212/WNL.0000000000001212 25568295 · DOI
  23. [28]Alcolea D The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: a data set for biomarker discovery and validation in neurodegenerative disorders Alzheimers Dement. 2019 5 597 609 10.1016/j.trci.2019.09.005 PMC6804606 31650016 · DOI

Cited by

Sorted by citations

Authors
Lleó, A., Zetterberg, H., Pegueroles, J., Karikari, T. K., Carmona-Iragui, M., Ashton, N. J., Montal, V., Barroeta, I., Lantero-Rodríguez, J., Videla, L., Altuna, M., Benejam, B., Fernandez, S., Valldeneu, S., Garzón, D., Bejanin, A., Iulita, M. F., Camacho, V., Medrano-Martorell, S., Belbin, O., Clarimon, J., Lehmann, S., Alcolea, D., Blesa, R., Blennow, K., & Fortea, J.
Affiliations
  • Universitat Autònoma de Barcelona (ES)
  • Sahlgrenska University Hospital (SE)
  • University of Gothenburg (SE)
  • King's College London (GB)
  • Inserm (FR)
Corresponding author
  • Lleó, Alberto
  • Fortea, Juan
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2021-07-14
Volume
12
Issue
1
Pages
4304-4304
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-021-24319-x
PMC
PMC8280160
OpenAlex
W3182940708
Cited by
72
References
6
Citations by year
2026: 12 · 2025: 16 · 2024: 15 · 2023: 13 · 2022: 12 · 2021: 4
FWCI
7.89
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, cc-by)
Funders
  • Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Pi14/01126)
  • Fundació la Marató de TV3 (20141210)
  • "la Caixa" Foundation
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
Keywords
phosphorylated tau 181, plasma biomarkers, Alzheimer's disease, Down syndrome, prodromal Alzheimer's disease, Alzheimer's dementia, diagnostic accuracy, Simoa assay, brain atrophy, neuroimaging biomarkers
MeSH terms
Adult, Alzheimer Disease, Atrophy, Cerebral Cortex, Cognition, Cross-Sectional Studies, Down Syndrome, Female, Humans, Male, Middle Aged, Phosphorylation, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neurofilament Proteins, Disease Progression, Area Under Curve

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review